lymphir
Generic: denileukin diftitox·Brand: Lymphir
lymphir: sourced relationships with 2 companies.
lymphir evidence translation
What we can confirm
No verified FDA or trial count is available.
What it means
More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Evidence is limited; missing information remains unknown.
BioSniper AIPage evidence connected
Prepared research question
What is verified about lymphir, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL)Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL); adult patients with relapsed or refractory Stage I-III CTCL
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (3)
| Company | Dated record stage |
|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) Treatment of patients with persistent or recurrent cutaneous… | Approved |
| CITIUS ONCOLOGY, INC. (CTOR) Treatment of patients with persistent or recurrent cutaneous… | Approved |
| Citius Pharmaceuticals, Inc. (CTXR) Treatment of patients with persistent or recurrent cutaneous… | Approved |